Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Retinal Imaging (RetAD)

Method of Measurement (Pre-analytical Tools)
Optical
Biomarker Measured
Vasculature
Use
Diagnostic
Monitoring
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

Examine if using the retina can act as a model organ to study the central nervous system (CNS).The investigators will build a longitudinal database of ocular, systemic, neuro-psychiatric, MRI and PET imaging parameters of Aβ-positive and Aβ-negative patients with different stages of cognitive impairment. This database will be used to provide proof-of-concept that retinal biomarkers provide an early, accurate and non-invasive tool for AD detection and follow-up.

Target Population/ Population Being Studied

Ab+ AD patients, Ab+ Mild Cognitive Impairment (MCI) patients, Ab+ cognitively intact volunteers, and Ab- cognitively intact volunteers

Length of Current Trial
2 years
Number of Trial Participants

90

Estimated Trial Completion
December 2020
What is Required from Patients

noninvasive images of the eye,, injected dyes, PET imagining of the eyes in clinic visit

What is Required from the Health System

eye tracking device, eye imager, eye PET scanner, dyes, technicians

Sponsor

Universitaire Ziekenhuizen Leuven

“Multimodal Retinal Imaging in the Detection and Follow-up of Alzheimer's Disease (RetAD)” ClinicalTrials.gov. Accessed October 11, 2019. https://clinicaltrials.gov/ct2/show/NCT03466177?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=3&rank=24